The Use of the Tumour Necrosis Factor Antagonist Infliximab in Heart Transplant Recipients: Two Case Reports

Annals of the Rheumatic Diseases - United Kingdom
doi 10.1136/ard.2007.070383
Full Text
Abstract

Available in full text

Date
Authors
Publisher

BMJ

Related search

Belatacept During Pregnancy in Renal Transplant Recipients: Two Case Reports

American Journal of Transplantation
TransplantationAllergyImmunologyPharmacology
2018English

Regadenoson in Heart Transplant Recipients: Use Without Worries

Journal of Nuclear Cardiology
Nuclear MedicineRadiologyCardiovascular MedicineImagingCardiology
2018English

Pulmonary Granulomas After Tumour Necrosis Factor Alpha Antagonist Therapy

Thorax
PulmonaryRespiratory Medicine
2003English

Tumour Necrosis Factor Gene Polymorphism: A Predictive Factor for the Development of Post-Transplant Lymphoproliferative Disease

British Journal of Cancer
Cancer ResearchOncology
2009English

The Risk of Tuberculosis Related to Tumour Necrosis Factor Antagonist Therapies: A TBNET Consensus Statement

European Respiratory Journal
MedicinePulmonaryRespiratory Medicine
2010English

The Importance of Cytomegalovirus in Heart-Lung Transplant Recipients

Chest
CardiologyCritical CareCardiovascular MedicineIntensive Care MedicinePulmonaryRespiratory Medicine
1989English

Cardiovascular Outcomes in Heart Transplant Recipients

Journal of Nuclear Cardiology
Nuclear MedicineRadiologyCardiovascular MedicineImagingCardiology
2019English

The Role of Biventricular Implantable Defibrillator in Heart Transplant Recipients

Journal of Cardiac Failure
Cardiovascular MedicineCardiology
2019English

Editorial: CT-P13, a Biosimilar of Anti-Tumour Necrosis Factor-Alpha Agent (Infliximab), in Inflammatory Bowel Diseases

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy